Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FHDC2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,792
Award facts
- Contract value 100% obligated
- $15,792.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $15,792.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The order was awarded on January 29, 2026, with an ultimate completion date of February 20, 2026, under a firm fixed-price contract type with no set-aside designation. DMS Pharmaceutical Group competes in the unrestricted federal procurement market, demonstrating sufficient competitive capability to win non-set-aside awards alongside other qualified vendors.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.9 billion ceiling through December 31, 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to provide pharmaceutical products and medical consumables to Department of Defense military healthcare facilities worldwide. As one of multiple regional prime vendor contractors under this framework, DMS Pharmaceutical Group supplies a comprehensive portfolio including branded and generic pharmaceuticals, biologics, vaccines, and specialty medical products to support the recurring pharmaceutical needs of the federal military medical system globally.
Quick answers
Who was awarded contract SPE2DR26FHDC2?
SPE2DR26FHDC2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FHDC2 worth?
The government has obligated $15,792 on SPE2DR26FHDC2.
Is contract SPE2DR26FHDC2 an order under another contract?
Yes. SPE2DR26FHDC2 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHDC2 competed?
The extent of competition for SPE2DR26FHDC2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award